Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.

Japan was never known for its healthcare-focused venture capital funds, but Whiz Partners, Inc. is looking to fill what it sees as a void, helped by some heavy corporate hitters, and a major new collaboration with Takeda's spun out preclinical development operations in Japan.